296 related articles for article (PubMed ID: 15852221)
1. Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis.
Savi P; Herbert JM
Semin Thromb Hemost; 2005 Apr; 31(2):174-83. PubMed ID: 15852221
[TBL] [Abstract][Full Text] [Related]
2. Platelet adenosine diphosphate receptor antagonists: ticlopidine to ticagrelor-a long continuing journey.
Kaul U; Mansoor AH
Indian Heart J; 2012; 64(1):54-9. PubMed ID: 22572427
[TBL] [Abstract][Full Text] [Related]
3. Adenosine diphosphate-inducible platelet reactivity shows a pronounced age dependency in the initial phase of antiplatelet therapy with clopidogrel.
Gremmel T; Steiner S; Seidinger D; Koppensteiner R; Panzer S; Kopp CW
J Thromb Haemost; 2010 Jan; 8(1):37-42. PubMed ID: 19818001
[TBL] [Abstract][Full Text] [Related]
4. Synergistic Inhibition of Both P2Y1 and P2Y12 Adenosine Diphosphate Receptors As Novel Approach to Rapidly Attenuate Platelet-Mediated Thrombosis.
Gremmel T; Yanachkov IB; Yanachkova MI; Wright GE; Wider J; Undyala VV; Michelson AD; Frelinger AL; Przyklenk K
Arterioscler Thromb Vasc Biol; 2016 Mar; 36(3):501-9. PubMed ID: 26743169
[TBL] [Abstract][Full Text] [Related]
5. Value of antiplatelet therapy in preventing thrombotic events in generalized vascular disease.
Montalescot G
Clin Cardiol; 2000 Nov; 23 Suppl 6(Suppl 6):VI-18-22. PubMed ID: 11129682
[TBL] [Abstract][Full Text] [Related]
6. Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist.
Husted S; van Giezen JJ
Cardiovasc Ther; 2009; 27(4):259-74. PubMed ID: 19604248
[TBL] [Abstract][Full Text] [Related]
7. The reversible P2Y antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function.
Dovlatova NL; Jakubowski JA; Sugidachi A; Heptinstall S
J Thromb Haemost; 2008 Jul; 6(7):1153-9. PubMed ID: 18485086
[TBL] [Abstract][Full Text] [Related]
8. Potentiation of clopidogrel active metabolite formation by rifampicin leads to greater P2Y12 receptor blockade and inhibition of platelet aggregation after clopidogrel.
Judge HM; Patil SB; Buckland RJ; Jakubowski JA; Storey RF
J Thromb Haemost; 2010 Aug; 8(8):1820-7. PubMed ID: 20492465
[TBL] [Abstract][Full Text] [Related]
9. Standardization of light transmittance aggregometry for monitoring antiplatelet therapy: an adjustment for platelet count is not necessary.
Linnemann B; Schwonberg J; Mani H; Prochnow S; Lindhoff-Last E
J Thromb Haemost; 2008 Apr; 6(4):677-83. PubMed ID: 18182038
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of the platelet P2Y12 receptor for adenosine diphosphate potentiates the antiplatelet effect of prostacyclin.
Cattaneo M; Lecchi A
J Thromb Haemost; 2007 Mar; 5(3):577-82. PubMed ID: 17155953
[TBL] [Abstract][Full Text] [Related]
11. Normalization of platelet reactivity in clopidogrel-treated subjects.
Vilahur G; Choi BG; Zafar MU; Viles-Gonzalez JF; Vorchheimer DA; Fuster V; Badimon JJ
J Thromb Haemost; 2007 Jan; 5(1):82-90. PubMed ID: 17239165
[TBL] [Abstract][Full Text] [Related]
12. Assessment of high on-treatment platelet reactivity in patients with ischemic heart disease: concordance between the Multiplate and VerifyNow assays.
Consuegra-Sánchez L; López-Palop R; Cano P; Carrillo P; Picó F; Villegas M; Sanchis J; Kaski JC
J Thromb Haemost; 2013 Feb; 11(2):379-81. PubMed ID: 23253198
[No Abstract] [Full Text] [Related]
13. Adenine triphosphate nucleotides are antagonists at the P2Y receptor.
Kauffenstein G; Hechler B; Cazenave JP; Gachet C
J Thromb Haemost; 2004 Nov; 2(11):1980-8. PubMed ID: 15550030
[TBL] [Abstract][Full Text] [Related]
14. Can the PFA-100 be modified to detect P2Y12 inhibition?
Pidcock M; Harrison P
J Thromb Haemost; 2006 Jun; 4(6):1424-6. PubMed ID: 16706997
[No Abstract] [Full Text] [Related]
15. Enhanced antiplatelet effect of clopidogrel in patients whose platelets are least inhibited by aspirin: a randomized crossover trial.
Eikelboom JW; Hankey GJ; Thom J; Claxton A; Yi Q; Gilmore G; Staton J; Barden A; Norman PE
J Thromb Haemost; 2005 Dec; 3(12):2649-55. PubMed ID: 16359503
[TBL] [Abstract][Full Text] [Related]
16. Antiplatelet therapy in the prevention of ischemic vascular events: literature review and evidence-based guidelines for drug selection.
Zusman RM; Chesebro JH; Comerota A; Hartmann JR; Massin EK; Raps E; Wolf PA
Clin Cardiol; 1999 Sep; 22(9):559-73. PubMed ID: 10486695
[TBL] [Abstract][Full Text] [Related]
17. Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases.
Aleil B; Ravanat C; Cazenave JP; Rochoux G; Heitz A; Gachet C
J Thromb Haemost; 2005 Jan; 3(1):85-92. PubMed ID: 15634270
[TBL] [Abstract][Full Text] [Related]
18. Protease activated receptor-1 (PAR-1) mediated platelet aggregation is dependent on clopidogrel response.
Kreutz RP; Breall JA; Kreutz Y; Owens J; Lu D; Bolad I; von der Lohe E; Sinha A; Flockhart DA
Thromb Res; 2012 Aug; 130(2):198-202. PubMed ID: 22459907
[TBL] [Abstract][Full Text] [Related]
19. Diabetes mellitus and platelet function after administration of aspirin and a single 600 mg dose of clopidogrel.
Sibbing D; von Beckerath O; Schömig A; Kastrati A; von Beckerath N
J Thromb Haemost; 2006 Dec; 4(12):2566-8. PubMed ID: 16938125
[No Abstract] [Full Text] [Related]
20. Evidence that pre-existent variability in platelet response to ADP accounts for 'clopidogrel resistance'.
Michelson AD; Linden MD; Furman MI; Li Y; Barnard MR; Fox ML; Lau WC; McLaughlin TJ; Frelinger AL
J Thromb Haemost; 2007 Jan; 5(1):75-81. PubMed ID: 17002661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
